NCT01760655 - Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 24, 2012

Primary Completion Date

April 15, 2022

Study Completion Date

December 5, 2022

Conditions

Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With Gene MutationsAcute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOMAcute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214Aplastic AnemiaChronic Lymphocytic LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Myelomonocytic LeukemiaFollicular LymphomaHodgkin LymphomaMyelodysplastic SyndromeMyelofibrosisMyeloid LeukemiaNon-Hodgkin LymphomaPlasma Cell MyelomaPolycythemia VeraRecurrent Adult Acute Myeloid LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid Leukemia

Interventions

DRUG

Fludarabine phosphate

Given IV

DRUG

Busulfan

Given IV

RADIATION

Total-Body Irradiation

Undergo TBI

BIOLOGICAL

Therapeutic Allogeneic Lymphocytes

Undergo DLI

DRUG

Cyclophosphamide

Given IV

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic PBSCT

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo allogeneic PBSCT

DRUG

Tacrolimus

Given IV

DRUG

Mycophenolate Mofetil

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER